Tyrosine kinase inhibitor useful in imatinib-refractory CML.(Hematology)(chronic myelogenous leukemia): An article from: Internal Medicine News
This digital document is an article from Internal Medicine News, published by Thomson Gale on January 15, 2007. The length of the article is 687 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: Tyrosine kinase inhibitor useful in imatinib-refractory CML.(Hematology)(chronic myelogenous leukemia)
Author: Bruce Wilson
Publication: Internal Medicine News (Magazine/Journal)
Date: January 15, 2007
Publisher: Thomson Gale
Volume: 40 Issue: 2 Page: 24(1)
Distributed by Thomson Gale
List Price: $ 9.95
Price: $ 9.95
Leukemia — Comprehensive overview covers symptoms, causes, risk factors, treatment of this blood-related cancer.
Tyrosine kinase inhibitor useful in imatinib-refractory CML.(Hematology)(chronic myelogenous leukemia): An article from: Internal Medicine News
Related Refractory Leukemia Products
Orignal From: Tyrosine kinase inhibitor useful in imatinib-refractory CML.(Hematology)(chronic myelogenous leukemia): An article from: Internal Medicine News Reviews
No comments:
Post a Comment